The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension
Frank Erhard Uschner(Goethe University Frankfurt), Jonel Trebicka(Klinik für Schlafmedizin), Glen Kristiansen(University Hospital Bonn), Robert Schierwagen(University of Münster), Thomas Ritz, Ivelina Nikolova(University of Bonn), Christoph Roderburg(Düsseldorf University Hospital), Florian Schueller(RWTH Aachen University), Sven H. Loosen(Düsseldorf University Hospital), Twan Lammers(RWTH Aachen University), Mihael Vucur(Düsseldorf University Hospital), Fernando Magdaleno(University of Bonn), Tom Luedde(Düsseldorf University Hospital), Sabine Klein(Goethe University Frankfurt), Stefanie Gröschl(University of Bonn)
Cited by 32
Related Papers
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.5k
NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
|Nature Reviews Gastroenterology & Hepatology|2011|1.4k
Tumor targeting via EPR: Strategies to enhance patient responses
|Advanced Drug Delivery Reviews|2018|1.2k
Smart cancer nanomedicine
|Nature Nanotechnology|2019|1.2k